Total Payments
$37,723
2024 Payments
$694.39
Companies
63
Transactions
522
Medicare Patients
7,951
Medicare Billing
$1.9M
Payment Breakdown by Category
Consulting$11,830 (31.4%)
Other$10,115 (26.8%)
Food & Beverage$7,446 (19.7%)
Travel$4,172 (11.1%)
Gifts$3,555 (9.4%)
Education$604.60 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,830 | 7 | 31.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,115 | 7 | 26.8% |
| Food and Beverage | $7,446 | 451 | 19.7% |
| Travel and Lodging | $4,172 | 15 | 11.1% |
| Gift | $3,555 | 34 | 9.4% |
| Education | $604.60 | 8 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seattle Genetics, Inc. | $7,557 | 11 | $0 (2019) |
| Janssen Biotech, Inc. | $4,054 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,898 | 61 | $0 (2024) |
| Exelixis Inc. | $3,337 | 5 | $0 (2022) |
| TESARO, Inc. | $2,959 | 8 | $0 (2017) |
| Celgene Corporation | $2,763 | 31 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,745 | 75 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $2,446 | 5 | $0 (2018) |
| Astellas Pharma US Inc | $2,173 | 22 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $881.04 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $694.39 | 43 | AstraZeneca Pharmaceuticals LP ($181.02) |
| 2023 | $1,256 | 68 | AstraZeneca Pharmaceuticals LP ($190.17) |
| 2022 | $3,881 | 45 | Exelixis Inc. ($3,337) |
| 2021 | $1,938 | 19 | AstraZeneca Pharmaceuticals LP ($1,680) |
| 2020 | $3,482 | 48 | Astellas Pharma US Inc ($1,870) |
| 2019 | $12,354 | 106 | Seattle Genetics, Inc. ($6,511) |
| 2018 | $6,940 | 104 | Janssen Scientific Affairs, LLC ($2,446) |
| 2017 | $7,179 | 89 | TESARO, Inc. ($2,959) |
All Payment Transactions
522 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Oncology | ||||||
| 12/03/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.05 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $18.80 | General |
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Oncology | ||||||
| 10/16/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Oncology | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Oncology | ||||||
| 09/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.81 | General |
| Category: Oncology | ||||||
| 09/03/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Oncology | ||||||
| 08/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Oncology | ||||||
| 07/23/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: Oncology | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Immunology | ||||||
| 06/06/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.70 | General |
| Category: Hematology | ||||||
| 06/04/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Oncology | ||||||
| 05/23/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Immunology | ||||||
| 05/21/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $15.29 | General |
| 05/14/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $15.18 | General |
| Category: Hematology/Oncology | ||||||
| 05/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Oncology | ||||||
| 05/07/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.90 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 2,167 | 22,507 | $1.0M | $413,206 |
| 2022 | 29 | 1,882 | 7,215 | $717,651 | $373,851 |
| 2021 | 32 | 1,831 | 8,501 | $831,452 | $417,824 |
| 2020 | 36 | 2,071 | 33,850 | $1.9M | $709,232 |
Total Patients
7,951
Total Services
72,073
Medicare Billing
$1.9M
Procedure Codes
132
All Medicare Procedures & Services
132 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 86 | 367 | $116,954 | $48,035 | 41.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 194 | 405 | $116,145 | $43,317 | 37.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 250 | 610 | $106,294 | $41,492 | 39.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 34 | 305 | $95,456 | $37,370 | 39.1% |
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 63 | 312 | $82,180 | $33,876 | 41.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 98 | 345 | $70,167 | $26,404 | 37.6% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 76 | 248 | $54,383 | $22,599 | 41.6% |
| 99350 | Residence visit for established patient with high level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 62 | 138 | $54,920 | $22,025 | 40.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 129 | 141 | $53,304 | $19,569 | 36.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 102 | 109 | $31,629 | $11,611 | 36.7% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 74 | 75 | $28,361 | $11,547 | 40.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 56 | 56 | $27,551 | $10,266 | 37.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 65 | $26,364 | $10,223 | 38.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 35 | 314 | $21,330 | $8,427 | 39.5% |
| 99345 | Residence visit for new patient with high level of medical decision making, per day, if using time, at least 75 minutes | Office | 2023 | 43 | 43 | $17,200 | $7,472 | 43.4% |
| 99316 | Nursing facility discharge management, more than 30 minutes | Facility | 2023 | 60 | 62 | $16,795 | $6,989 | 41.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 220 | 844 | $6,902 | $6,613 | 95.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 14 | 107 | $16,282 | $6,523 | 40.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 215 | 802 | $13,133 | $6,096 | 46.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 57 | $15,499 | $5,866 | 37.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 23 | 80 | $11,944 | $4,729 | 39.6% |
| 99348 | Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 20 | 73 | $11,510 | $4,571 | 39.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 136 | $8,909 | $3,578 | 40.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 22 | 233 | $8,339 | $3,362 | 40.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,792 | $2,094 | 36.2% |
About Dr. James Orsini, M.D
Dr. James Orsini, M.D is a Internal Medicine healthcare provider based in Belleville, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1659516813.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Orsini, M.D has received a total of $37,723 in payments from pharmaceutical and medical device companies, with $694.39 received in 2024. These payments were reported across 522 transactions from 63 companies. The most common payment nature is "Consulting Fee" ($11,830).
As a Medicare-enrolled provider, Orsini has provided services to 7,951 Medicare beneficiaries, totaling 72,073 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 132 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Belleville, NJ
- Active Since 12/02/2008
- Last Updated 04/10/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1659516813
Products in Payments
- Erleada (Drug) $6,393
- KISQALI (Drug) $3,488
- Cabometyx (Drug) $3,337
- VARUBI (Drug) $2,955
- Abraxane (Drug) $2,510
- TAGRISSO (Drug) $1,938
- PADCEV (Drug) $1,640
- Adcetris (Biological) $1,046
- Nubeqa (Drug) $745.00
- KEYTRUDA (Biological) $401.05
- OPDIVO (Biological) $393.28
- JAKAFI (Drug) $324.81
- XTANDI (Drug) $302.23
- LYNPARZA (Drug) $294.45
- IMFINZI (Drug) $243.51
- JEVTANA (Drug) $235.53
- Xtandi (Drug) $182.37
- ZYTIGA (Drug) $149.95
- Lenvima (Drug) $145.94
- Kyprolis (Drug) $139.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Belleville
Ahmed Hussein, Md, MD
Internal Medicine — Payments: $30,729
Internal Medicine $30,729
Nidal Shawahin, Md, MD
Internal Medicine — Payments: $29,277
Internal Medicine $29,277
Kashif Bhutto, Md, MD
Internal Medicine — Payments: $18,942
Internal Medicine $18,942
Nader Moaven, Md, MD
Internal Medicine — Payments: $16,925
Internal Medicine $16,925
Matthew Hageman, Md, MD
Internal Medicine — Payments: $13,597
Internal Medicine $13,597
Sameer Kaul, M.d, M.D
Internal Medicine — Payments: $5,273
Internal Medicine $5,273